An integrated cell and protein engineering approach to generate enhanced CHO cell platforms for manufacture of difficult to express biopharmaceuticals

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Recombinant produced protein-based biotherapeutics are a huge commercial success, particularly of monoclonal antibodies that dominate the market. As such, the cost (and certainty) of production is relatively fixed for standard antibody-based biotherapeutics and there is predictability and robustness. However, the market is changing and estimates are that 50-60% of all biotherapeutic products in development are non-standard molecules, referred to as novel format (or colloquially as "difficult-to-express") biotherapeutics. Such molecules are generated by application of protein engineering, taking molecular domains and structures of desirable feature (for molecular targeting, functional activity, therapeutic longevity, ease of production) to build a product of non-natural (but potential great efficacy) for production by genetic manipulation of host cell types. The potential for this has not been realized due to low and unpredictable expression of many novel format molecules. This is the focus of the current application. In this project, we will (a) develop a systems level understanding of features that recognise protein quality "acceptability" in particular CHO cell background(s), (b) identify molecular features that enable early selection of "good" clones following transfections, design pipelines for re-engineering CHO cells to generate improved expression of defined novel protein domain builds, (c) develop a greater understanding of the multi-facetted interactive cell background that regulates cell fate, survival and secretion in the industrial context, (d) develop protein engineering strategies, specifically around glycosylation of proteins (and domains) to modify the rate or capacity for secretion of specific difficult to express proteins, and (e) deliver a suite of new CHO cell hosts and protein engineered molecule formats validated for enhanced industrial production and quality of DTE biotherapeutics.

Increased fundamental understanding of cell factories for predictable production of the next generation of novel biotherapeutics will lead to more effective treatment of patients with diseases that may currently be untreatable or without complete cure. The understanding gained (along with the potential to apply synthetic biology approaches to re-engineer the Chinese hamster ovary cell factory or to rationalize the structure of novel biotherapeutics) has immediate implication and long-term potential application. The immediate beneficiaries include the academic and industrial community that is actively addressing approaches for more robust production of novel biotherapeutics. In the longer term, via translation of the research findings into development and manufacturing processes, there will be better therapeutics for patients. Commercially, greater reassurance and, hence, speed to market will decrease the cost of manufacture of new medicines, with implications towards the cost of therapy for health agencies and, ultimately, for the well-being of patient cohorts. The UK is recognized as a leading player (both academically and industrially) across the international sector for research into, and manufacture of, biotherapeutics, a market with sales of $140Bn in 2013. This research, as a collaboration with UCB (one of the world-leading producers of biotherapeutics), will help the UK to maintain its status as an innovator for biotherapeutics. A major outcome of the project will be to highlight the strong industrial-academic collaborative ethos in the UK and the manner in which BBSRC industrial-academic funding initiatives ensure long-term retention of strong UK-based industrial research focus for multi-national companies. At a training level, the PDRAs funded under this LINK project will be embedded into the laboratory environment of UCB for the early stages of the research. They will gain experience of the industrial perspective of direct commercial relevance of the discovery, development and manufacturing focus and will be exposed to the broader UCB environment, participating in project team meetings and attending workshops on technology and enterprise development, drug discovery and commercialization.

Project partners have discussed and accepted a strategy for knowledge exchange and data dissemination. All partners are members of other existing successful collaborations (with a mixture of industrial and academic partners) and have used a range of knowledge exchange pathways to disseminate data and results of potentially commercial-sensitive information in modes that satisfy the needs of all participants (and research funders). A 3-way contract between Kent, Manchester and UCB will develop agreed ownership of intellectual property (IP) and responsibility for its application, ensuring that the support of BBSRC can be acknowledged and that knowledge generated in the project can be disseminated in an appropriate manner. With the contract in place, the project team (and, wherever possible, specifically the PDRA) will disseminate outputs via peer-reviewed publications and at research conferences. This will include UK-based sector networks e.g. BioProNET (http://www.biopronetuk.org) and other Networks in Industrial Biotechnology and Bioenergy (NIBB), bioProcessUK (http://www.bioprocessuk.org) and ESACT UK (http://www.esactuk.org.uk). Internationally, presentations will be made at the two premier sector conferences (ESACT, http://www.esact.org and ECI, Cell Culture Engineering, http://www.engconf.org/conferences/biotechnology/cell-culture-engineering-xv/). The wider Industrial Biotechnology (IB) community will be engaged through the IB Leadership forum (https://connect.innovateuk.org/web/industrial-biotechnology) and we will develop public engagement activities through outreach activities (specifically in Kent and Manchester via the Public Open Days and via the UCB website that has a patient-inspired focus).